Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of first episode psychosis: a randomized double blind 52-week comparison

Trial Profile

Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of first episode psychosis: a randomized double blind 52-week comparison

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2010

At a glance

  • Drugs Olanzapine; Quetiapine; Risperidone
  • Indications Cognition disorders; Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms CAFE
  • Most Recent Events

    • 29 Nov 2010 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 29 Nov 2010 Actual end date (Mar 2005) added as reported by ClinicalTrials.gov.
    • 29 Nov 2010 Actual initiation date (Mar 2002) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top